Erythropoietin mimics ischemic preconditioning (Q36142638)

12 August 2017

1 reference

title

Erythropoietin mimics ischemic preconditioning (English)

1 reference

12 August 2017

1 reference

John E Baker

1

1 reference

12 August 2017

17 March 2005

1 reference

12 August 2017

Vascular Pharmacology

1 reference

12 August 2017

42

1 reference

12 August 2017

233-241

1 reference

12 August 2017

5-6

1 reference

The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Erythropoietin regulates endothelial progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Increased tolerance of the chronically hypoxic immature heart to ischemia. Contribution of the KATP channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Cytokine G-protein signaling crosstalk in cardiomyocytes: attenuation of Jak-STAT activation by endothelin-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Pharmacokinetics of recombinant human erythropoietin in children with chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Erythropoietin activates two distinct signaling pathways required for the initiation and the elongation of c-myc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Activation of Raf-1 and mitogen-activated protein kinases by erythropoietin and inositolphosphate-glycan in normal erythroid progenitor cells: involvement of protein kinase C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Pharmacokinetics of Recombinant Human Erythropoietin in Children with Renal Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Akt negatively regulates translation of the ternary complex factor Elk-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Akt2 Negatively Regulates Assembly of the POSH-MLK-JNK Signaling Complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Ischemic preconditioning protects by activating prosurvival kinases at reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Intraperitoneal erythropoietin in children on peritoneal dialysis: A study of pharmacokinetics and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Derivatives of erythropoietin that are tissue protective but not erythropoietic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Timing of Erythropoietin Treatment for Cardioprotection in Ischemia/Reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

14-3-3 is not essential for Raf-1 function: identification of Raf-1 proteins that are biologically activated in a 14-3-3- and Ras-independent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

ATP-regulated K+ channels in cardiac muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

A novel protective effect of erythropoietin in the infarcted heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Activation of protein kinases in chronically hypoxic infant human and rabbit hearts: role in cardioprotection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Pharmacokinetics of recombinant human erythropoietin in children treated with continuous ambulatory peritoneal dialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Ischemia-induced STAT-1 Expression and Activation Play a Critical Role in Cardiomyocyte Apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Activation of mitogen-activated protein kinase cascade through erythropoietin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Nitric oxide-dependent pulmonary vasodilation in polycythemic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Small peptides as potent mimetics of the protein hormone erythropoietin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Increased potency of an erythropoietin peptide mimetic through covalent dimerization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Relationship between erythropoietin and nitric oxide in the contraction of rat renal arcuate arteries and human umbilical vein endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Cytoprotective role of Ca2+- activated K+ channels in the cardiac inner mitochondrial membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

An essential role of the JAK-STAT pathway in ischemic preconditioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

STAT signaling in ischemic heart: a role of STAT5A in ischemic preconditioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

Phosphorylation and regulation of Raf by Akt (protein kinase B)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.004

10.1016/J.VPH.2005.02.004

7 January 2021

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15922256